

P-63

**ACUTE TOXICITY STUDIES OF A NEW HBV  
IMMUNOTHERAPEUTIC AGENT MBRI-98304 IN RATS AND  
BEAGLE DOGS**

Zai-Zhi Huang, Eun-Yong Jung, Hu-Song Zhang, Dae-Joong Kim, Sang-Yoon Nam, and  
Jong-Koo Kang

College of Veterinary Medicine, Chungbuk National University, Cheongju 361-763, Korea

The acute toxicity study of MBRI-98304, a new Hepatitis B virus (HBV) immunotherapeutic agent, was performed in Sprague-Dawley rats (7 weeks old) and Beagle dogs (4 months old). MBRI-98304 was injected intramuscularly at a single dosage of 0, 20, 100, 500, 2,500, and 12,500  $\mu\text{g}/\text{kg}$  in rats and 0, 200, 1,000, and 5,000  $\mu\text{g}/\text{kg}$  in Beagle dogs for 2 weeks daily. There were no deaths or clinical signs. There were no significant changes in body weight. Specific gross and histopathological changes were not observed in the livers of animals treated with MBRI-98304. From these results, we suggest that MBRI-98304 may be no side effects and its LD50 value may be over 12,500  $\mu\text{g}/\text{kg}/\text{day}$  in rats or 5,000  $\mu\text{g}/\text{kg}/\text{day}$  in Beagle dogs.